Free
All Subscriber Access
BiQ: The Ziftomenib-Revumenib Debate 12/10/25 (KURA, SNDX)
BiQ: BiQ Annual Subscription Pricing
BiQ: Discontinuing Support for the BiQ Public Chat Server
BiQ: 11/25/25 Additional Thoughts on Capricor (CAPR)
BiQ: 11/25/25 The Deramiocel Debate (CAPR)
BiQ: 11/23/25 Quick Update on NeuroPace (NPCE)
BiQ: 11/23/25 Lyell Immunopharma Upcoming Catalysts (LYEL)
BiQ: A Few Thoughts on Current Market Conditions and Market Liquidity
BiQ Journal for November 8, 2025
BiQ: Some Thoughts on Today's Biotech Selloff (11/03/25)